For years, Danish head and neck cancer patients have had their chances of overcoming their cancer therapy improved by an add-on treatment to radiotherapy. Danish biotech company Azanta has now received Orphan Drug Designation, which will facilitate the dissemination of the treatment for the benefit of a wide range of patients worldwide.
Press release, July 14, 2011.
The EU Commission has granted the so-called Orphan Drug Status to the specialty pharma company Azanta's t ...
Satisfied Users & 
Approved Press Releases
